KUALA LUMPUR, March 29 (Bernama) -- JSR Corporation, the parent company of Crown Bioscience, a global drug discovery and development services company, has entered into a strategic partnership with Hubrecht Organoid Technology (HUB).
Under the agreement, CrownBio has an exclusive licence to provide pre-clinical oncology drug development and validation services using HUB Organoid Technology, including access to HUB’s highly characterised tumour organoid biobank.
CrownBio and HUB will also launch a collaborative research and development programme to accelerate further development of Organoid Technology, while CrownBio establishes a new operations centre in Utrecht, Netherlands.
Building on a global leadership in Patient-Derived Xenografts (PDX), CrownBio will offer comprehensive pharmacology and translational services based on HUB Organoid Technology.
The services will establish a unique platform that incorporates in vitro screening of Patient-Derived Organoids and PDX derived organoids, matched to downstream in vivo models.
CrownBio chief executive officer, Dr Jean-Pierre Wery said the partnership positioned the company at the forefront of global preclinical research by creating an unparalleled translational platform to accelerate drug development and validation.
Meanwhile, HUB executive director, Dr Robert Vries said the partnership equipped the drug development community with powerful new translational tools to guide the creation of novel and improved treatments for cancer.
-- BERNAMA
No comments:
Post a Comment